The latest in precision prevention news, curated for CancerIQ's community of oncologists, genetic counselors, breast centers, primary care providers, and anyone interested in staying ahead of cancer.
- All colorectal cancer patients require germline testing at diagnosis and somatic testing at advanced disease diagnosis via The Cancer Letter
“The adoption of universal germline and somatic MGPT screening for colorectal cancer ... would lead to a dramatic increase in testing, the need to accurately interpret the results, and equitable access to follow-up care. It is estimated that there would be 80,000 incremental germline tests done per year in the U.S.”
Offering genetic testing services to all patients diagnosed with CRC is the right thing to do. But, it requires offering providers templated processes within their workflow, and empowering them to manage these patients and their families long-term. We’ve found that it’s not only cost effective — it can actually generate revenue for cancer centers. As the latest evidence based guidelines around testing CRC patients continue to evolve quickly, now is the time to start putting the tools in place to start or scale your genetics program.
We're thankful to Fight Colorectal Cancer for their advocacy on this life-saving initiative.
- How A Genetic Test Saved This Black Woman’s Life via Essence
Ashley Dedmon was managed by a high-risk oncologist, received her first mammogram at 22, and genetic testing revealed she had a BRCA2 mutation. A personalized cancer risk prevention & managed care plan empowered her to live fully and later receive a a prophylactic double mastectomy.
“Breast cancer aggressively attacked three generations of women and I didn’t know why they all succumbed to the disease,” she says. “I needed to get to work and ask questions to protect my health.”
Breast centers partnering with CancerIQ to implement and scale their high-risk breast programs are working to ensure patients with increased hereditary or lifestyle risk, like Dedmon, are not missed.
- Forget Moonshot: Cancer Patients Right Now Need 'Groundshot' via MedScape
Cancer Groundshot is the equally important counterpart concept to the President's Cancer Moonshot. Robin Yabroff, PhD, MBA, scientific vice president of health services research at the American Cancer Society says, "it highlights the opportunity ... of thinking of highly effective but underutilized cancer control interventions."
The at-scale personalized cancer prevention we provide through CancerIQ is one control intervention that empowers cancer centers to primary care settings in identifying and stratifying risk, managing care, and providing clinical guidance end-to-end.
The results of a new, large-scale registry-based case-control study suggest that pathogenic variants in BRCA1 and BRCA2 are associated with increased risk of biliary tract, gastric, and esophageal cancers. The authors write that these risk association findings "are relevant for developing and adapting guidelines about genetic testing, treatment options, and treatability with PARP inhibitors for each cancer type."
As new evidence-based guidelines evolve alongside the broader clinical relevance of genetic testing, providers will need to clinically manage their patients' personalized cancer risk assessment and prevention plans at scale. We've learned that they need tools that help them work intuitively and in-line with their established workflows to achieve this.
- Why Healthcare Providers Must Embrace Precision Medicine Or Risk Losing A Competitive Edge via Forbes
"In the quest for precision medicine], providers must overcome the top three challenges," including educating physicians about it, integrating it into the clinical workflow, and developing a business model for it, says author Alexander Shlyankevich.
Just one-fifth of care organizations have precision medicine programs in place. But, to stay ahead of cancer, providers need to pre-empt disease with precision prevention. CancerIQ offers healthcare systems the business model, algorithm, and clinical decision guidance offering physicians in-platform education to make this possible.
- Amazon Involved With New Cancer Vaccine Clinical Trial via MedScape
A new clinical trial from tech giant Amazon & Fred Hutchinson Cancer Research Center aims to develop "personalized vaccines" to treat breast cancer and melanoma. Precision medicine is on its way to becoming the standard of care – and it starts with precision prevention.
Don't wait until the end of the month for stories like these. Stay up-to-date with the latest in precision prevention news. Follow CancerIQ on social media to be the first to see our curated content on cancer prevention, precision medicine & oncology, health equity, and more.
Follow Cancer IQ on Social Media